쿼드메디슨

464490KOSDAQ기초 의약물질 제조업

47.3 / 100

Reference Date: 2026-06-10

Financial Score11.0 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure12.0 / 15

AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Plunged 36.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

QuadMedison develops next-generation drug delivery systems using micro needle platform technology, expanding its business through Contract Development and Manufacturing Organization (CDMO) agreements with pharmaceutical companies. The company's core technologies, including S-MAP, C-MAP, and P-MAP, enhance medication compliance and offer innovative solutions for vaccines and synthetic pharmaceuticals.

Number of Employees

90people

Average Salary

51.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

2.84Industry Average 1.741.0Point

1.6x industry avg (risky)

ROE

-32.69Industry Average -6.033.5Point

5.4x industry avg (excellent)

Debt Ratio

31.04Industry Average 6.620.0Point

4.7x industry avg (risky)

Trend 2024~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.0% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼43.5% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -40.5% (improving, 2yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
쿼드메디슨, OLED 융합 마이크로니들 특허 출원
쿼드메디슨의 OLED 마이크로니들 특허 출원으로 차세대 바이오 기술 혁신 기대.
Positive
쿼드메디슨, 마이크로니들 세계적 권위자 초청 강연
쿼드메디슨이 마이크로니들 분야의 세계적 전문가를 초청하여 강연을 개최함으로써 기술 리더십과 혁신성을 강조하였다.
Positive
쿼드메디슨, 에피네프린 마이크로니들 생산장비 계약 체결
쿼드메디슨이 응급 의약품 에피네프린 마이크로니들패치 생산장비 계약으로 상업화 확대 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 7,630Won52-week high 24,55052-week low 7,630

1-month return0.0Point

1m -36.42% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 1Neutral 2Negative 0

Neutral기업설명회(IR)개최2026-05-22
Positive단일판매ㆍ공급계약체결2026-05-15
Neutral분기보고서 (2026.03)2026-05-15